TOKYO - A Japanese health ministry panel approved on Friday expanding the use of the U.S. pharmaceutical maker Pfizer Inc.'s COVID-19 vaccine for people aged 12 to 15 in addition to those 16 or older.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
